Cargando…

Prognostic factors for patients treated with abiraterone

AIM: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). METHODS: Retrospective evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvim, Cecília M, Mansinho, André, Paiva, Rita S, Brás, Raquel, Semedo, Patrícia M, Lobo-Martins, Soraia, da Ponte, Carolina B, Macedo, Daniela, Ribeiro, Leonor, dos Reis, José P, Fernandes, Isabel, Costa, Luís
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997918/ https://www.ncbi.nlm.nih.gov/pubmed/32025327 http://dx.doi.org/10.2144/fsoa-2019-0079

Ejemplares similares

Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
por: Fernandes, Isabel, et al.
Publicado: (2021)

Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal
por: Lopes-Brás, Raquel, et al.
Publicado: (2022)

Immunotherapy in Metastatic Mucosal Melanoma with Disseminated Intravascular Coagulation: A Case of Success
por: Luna Pais, Helena, et al.
Publicado: (2021)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
por: Lobo-Martins, Soraia, et al.
Publicado: (2020)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
por: Soares do Brito, Joaquim, et al.
Publicado: (2022)

Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive Entities
por: Esperança-Martins, Miguel, et al.
Publicado: (2023)

The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
por: Ferreira, Arlindo, et al.
Publicado: (2016)

Abiraterone Acetate
Publicado: (2012)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Targeting Inhibitor of Apoptosis Proteins to Overcome Chemotherapy Resistance—A Marriage between Targeted Therapy and Cytotoxic Chemotherapy
por: Barroso, Tiago, et al.
Publicado: (2023)

Abiraterone: moving up in line?
por: Strijbos, Michiel
Publicado: (2018)

Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
por: Gonçalves, Lisa, et al.
Publicado: (2023)

Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal cancer evolution and metastatic development
por: Sobral, Daniel, et al.
Publicado: (2022)

Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma
por: Melo-Alvim, Cecília, et al.
Publicado: (2022)

Identification of biomarkers predictive of metastasis development in early-stage colorectal cancer using network-based regularization
por: Peixoto, Carolina, et al.
Publicado: (2023)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

Late Onset of Abiraterone Severe Hypokalemia Due to Unsuspected ACTH-Secreting NEC
por: Toral, Fernando Pazos, et al.
Publicado: (2021)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
por: Gauthier, Hélène, et al.
Publicado: (2012)

Quadriplegia secondary to abiraterone-induced severe hypokalemia
por: Rajvanshi, Jignesh B., et al.
Publicado: (2019)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Abiraterone-Induced Hypokalemia: A Case Report
por: Nkwocha, Bernard I, et al.
Publicado: (2023)

Post-angiography headaches
por: Gil-Gouveia, Raquel Santos, et al.
Publicado: (2008)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Design and Molecular Modeling of Abiraterone-Functionalized Gold Nanoparticles
por: Stolarczyk, Elżbieta U., et al.
Publicado: (2018)

Design of Therapeutic Self-Assembled Monolayers of Thiolated Abiraterone
por: Stolarczyk, Elżbieta U., et al.
Publicado: (2018)

Low-Dose Abiraterone, a Rare European Commodity
por: Peters, Niamh, et al.
Publicado: (2020)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)
por: Banerjee, Susana, et al.
Publicado: (2020)

The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients
por: Liu, Ying, et al.
Publicado: (2022)

HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome
por: Golkaram, Mahdi, et al.
Publicado: (2021)

Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases
por: Mansinho, André, et al.
Publicado: (2019)

Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review
por: Mansinho, André, et al.
Publicado: (2022)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases
por: Soares do Brito, Joaquim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9v9c5cvtgcbui0d7kaj9lrfact